M Lehmann1, K Ashworth2, M Manco-Johnson2, J Di Paola2,3, K B Neeves1,2, C J Ng2. 1. Chemical and Biological Engineering, Colorado School of Mines, Golden, CO, USA. 2. Pediatrics, University of Colorado Denver, Aurora, CO, USA. 3. Human Medical Genetics and Genomics, University of Colorado Denver, Aurora, CO, USA.
Abstract
Essentials von Willebrand factor (VWF) function is shear stress dependent. Platelet accumulation in a microfluidic assay correlates with VWF levels. The microfluidic assay discriminates type 1 von Willebrand disease from healthy controls. The microfluidic flow assay detects responses to therapeutic intervention (DDAVP). SUMMARY: Background von Willebrand disease (VWD) is a mucocutaneous bleeding disorder with a reported prevalence of 1 in 10 000. von Willebrand factor (VWF) function and platelet adhesion are regulated by hemodynamic forces that are not integrated into most current clinical assays. Objective We evaluated whether a custom microfluidic flow assay (MFA) can screen for deficiencies in VWF in patients presenting with mucocutaneous bleeding. Methods Whole blood from individuals with mucocutaneous bleeding was assayed in a custom MFA. Results Thirty-two patients with type 1 VWD (10/32) or reported mucocutaneous bleeding were enrolled. The platelet adhesion velocity (r = 0.5978 for 750 s-1 and 0.6895 for 1500 s-1 ) and the maximum platelet surface area coverage (r = 0.5719 for 750 s-1 and 0.6633 for 1500 s-1 ) in the MFA correlated with VWF levels. Furthermore, the platelet adhesion velocity at 750 s-1 (type 1 VWD, mean 0.0009761, 95% confidence interval [CI] 0.0003404-0.001612; control, mean 0.003587, 95% CI 0.002455-0.004719) and at 1500 s-1 (type 1 VWD, mean 0.0003585, 95% CI 0.00003914-0.0006778; control, mean 0.003132, 95% CI 0.001565-0.004699) differentiated type 1 VWD from controls. Maximum platelet surface area coverage at 750 s-1 (type 1 VWD, mean 0.1831, 95% CI 0.03816-0.3281; control, mean 0.6755, 95% CI 0.471-0.88) and at 1500 s-1 (type 1 VWD, mean 0.07873, 95% CI 0.01689-0.1406; control, mean 0.6432, 95% CI 0.3607-0.9257) also differentiated type 1 VWD from controls. We also observed an improvement in platelet accumulation after 1-desamino-8-d-arginine vasopressin (DDAVP) treatment at 1500 s-1 (pre-DDAVP, mean 0.4784, 95% CI 0.1777-0.7791; post-DDAVP, mean 0.8444, 95% CI 0.7162-0.9726). Conclusions These data suggest that this approach can be used as a screening tool for VWD.
Essentialsvon Willebrand factor (VWF) function is shear stress dependent. Platelet accumulation in a microfluidic assay correlates with VWF levels. The microfluidic assay discriminates type 1 von Willebrand disease from healthy controls. The microfluidic flow assay detects responses to therapeutic intervention (DDAVP). SUMMARY: Background von Willebrand disease (VWD) is a mucocutaneous bleeding disorder with a reported prevalence of 1 in 10 000. von Willebrand factor (VWF) function and platelet adhesion are regulated by hemodynamic forces that are not integrated into most current clinical assays. Objective We evaluated whether a custom microfluidic flow assay (MFA) can screen for deficiencies in VWF in patients presenting with mucocutaneous bleeding. Methods Whole blood from individuals with mucocutaneous bleeding was assayed in a custom MFA. Results Thirty-two patients with type 1 VWD (10/32) or reported mucocutaneous bleeding were enrolled. The platelet adhesion velocity (r = 0.5978 for 750 s-1 and 0.6895 for 1500 s-1 ) and the maximum platelet surface area coverage (r = 0.5719 for 750 s-1 and 0.6633 for 1500 s-1 ) in the MFA correlated with VWF levels. Furthermore, the platelet adhesion velocity at 750 s-1 (type 1 VWD, mean 0.0009761, 95% confidence interval [CI] 0.0003404-0.001612; control, mean 0.003587, 95% CI 0.002455-0.004719) and at 1500 s-1 (type 1 VWD, mean 0.0003585, 95% CI 0.00003914-0.0006778; control, mean 0.003132, 95% CI 0.001565-0.004699) differentiated type 1 VWD from controls. Maximum platelet surface area coverage at 750 s-1 (type 1 VWD, mean 0.1831, 95% CI 0.03816-0.3281; control, mean 0.6755, 95% CI 0.471-0.88) and at 1500 s-1 (type 1 VWD, mean 0.07873, 95% CI 0.01689-0.1406; control, mean 0.6432, 95% CI 0.3607-0.9257) also differentiated type 1 VWD from controls. We also observed an improvement in platelet accumulation after 1-desamino-8-d-arginine vasopressin (DDAVP) treatment at 1500 s-1 (pre-DDAVP, mean 0.4784, 95% CI 0.1777-0.7791; post-DDAVP, mean 0.8444, 95% CI 0.7162-0.9726). Conclusions These data suggest that this approach can be used as a screening tool for VWD.
Authors: Giancarlo Castaman; Alberto Tosetto; Anne Goodeve; Augusto B Federici; Stefan Lethagen; Ulrich Budde; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; David Habart; Frank Hill; Ian Peake; Francesco Rodeghiero Journal: Br J Haematol Date: 2010-08-25 Impact factor: 6.998
Authors: T Quiroga; M Goycoolea; S Belmont; O Panes; E Aranda; P Zúñiga; J Pereira; D Mezzano Journal: J Thromb Haemost Date: 2014-06-27 Impact factor: 5.824
Authors: S W Schneider; S Nuschele; A Wixforth; C Gorzelanny; A Alexander-Katz; R R Netz; M F Schneider Journal: Proc Natl Acad Sci U S A Date: 2007-04-30 Impact factor: 11.205
Authors: K Nogami; K Ogiwara; K Yada; Y Shida; M Takeyama; H Yaoi; H Minami; S Furukawa; K Hosokawa; M Shima Journal: J Thromb Haemost Date: 2016-03-15 Impact factor: 5.824
Authors: K B Neeves; S F Maloney; K P Fong; A A Schmaier; M L Kahn; L F Brass; S L Diamond Journal: J Thromb Haemost Date: 2008-10-07 Impact factor: 5.824
Authors: Keith B Neeves; Abimbola A Onasoga; Ryan R Hansen; Jessica J Lilly; Diana Venckunaite; Meghan B Sumner; Andrew T Irish; Gary Brodsky; Marilyn J Manco-Johnson; Jorge A Di Paola Journal: PLoS One Date: 2013-01-23 Impact factor: 3.240
Authors: Isabella Provenzale; Sanne L N Brouns; Paola E J van der Meijden; Frauke Swieringa; Johan W M Heemskerk Journal: Micromachines (Basel) Date: 2019-11-16 Impact factor: 2.891
Authors: Floor C J I Heubel-Moenen; Sanne L N Brouns; Linda Herfs; Lara S Boerenkamp; Natalie J Jooss; Rick J H Wetzels; Paul W M Verhezen; Patric Machiels; Karyn Megy; Kate Downes; Johan W M Heemskerk; Erik A M Beckers; Yvonne M C Henskens Journal: Br J Haematol Date: 2022-01-10 Impact factor: 8.615
Authors: Brady M Trevisan; Christopher D Porada; Anthony Atala; Graça Almeida-Porada Journal: Semin Cell Dev Biol Date: 2020-06-18 Impact factor: 7.499